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Abstract
Purpose To examine the effects of a multi-factorial,
intensiﬁed treatment on self-reported health status, treat-
ment satisfaction, and diabetes-related distress in screen-
detected type 2 diabetes patients.
Methods Cluster-randomised controlled trial; A total of
498 screen-detected type 2 diabetes patients from 79 gen-
eral practices were assigned to intensiﬁed (n = 255) or
routine treatment according to Dutch guidelines (n = 243).
At baseline and after 3 years, patients completed the Short
Form-36 and the European Quality of Life-5 Dimensions
questionnaires. After 4.5 years, patients completed the
Diabetes Treatment Satisfaction Questionnaire and the
Problem Areas In Diabetes scale. We analysed the effects
of intensiﬁed treatment on self-rated health status, treat-
ment satisfaction, and diabetes-related distress, using
random effects models to account for clustering at practice
level.
Results Three to 5 years after type 2 diabetes was
detected by screening, there were no differences between
intensiﬁed and routine treatment in self-reported health
status, treatment satisfaction, and diabetes-related distress.
Conclusions Multi-factorial, intensiﬁed treatment did not
inﬂuence self-rated health status, treatment satisfaction,
and distress in screen-detected type 2 diabetes patients.
Therefore, health care professionals do not have to fear
negative effects of an intensiﬁed treatment on these
psychological outcomes.
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Abbreviations
T2DM Type 2 diabetes mellitus
UKPDS UK prospective diabetes study
ADDITION study Anglo-Danish-Dutch study of
intensive treatment in people with
screen-detected diabetes in primary
care
IT Intensiﬁed multi-factorial treatment
RC Routine care
SF-36 Medical outcomes study 36-item
short form health survey
EQ5D European quality of life-5 dimensions
DTSQ Diabetes treatment satisfaction
questionnaire
PAID Problem areas in diabetes scale
Introduction
Type 2 diabetes mellitus (T2DM) is related to worsened
psychological outcomes, especially in case of complica-
tions [1, 2], but the effects of intensive treatment are not
known. Intensive treatment of hyperglycaemia, hyper-
tension, and dyslipidaemia can reduce cardiovascular
disease in T2DM patients on the long run [3] and thus
may improve psychological outcomes. However, T2DM
patients may experience the need to take large quantities
of medication as a burden, which can lead to psycho-
social stress [4] and presumably less satisfaction with
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DOI 10.1007/s11136-010-9604-xtreatment. This may especially be so in screen-detected
patients, who do not have complaints, but still have to
take medication. Examination of psychological outcomes
showed that in screen-detected patients, intensiﬁed
treatment led to more anxiety and less self-efﬁcacy in
the ﬁrst year after diagnosis [5]. The UK Prospective
Diabetes Study (UKPDS) found no impact of intensiﬁed
treatment on perceived health in screen-detected patients,
although health status was affected by complications of
the disease [6].
In the ADDITION study (Anglo-Danish-Dutch Study
of Intensive Treatment in People with Screen-Detected
Diabetes in Primary Care), an intensiﬁed, multi-factorial
treatment of screen-detected T2DM patients is compared
with usual care according to national guidelines [7]. In
the current study, we investigated the effects of
3–4 years of intensiﬁed pharmacological treatment com-
bined with lifestyle advices on self-reported health status,
treatment satisfaction, and diabetes-related distress in
screen-detected T2DM patients in the ADDITION-Neth-
erlands study. The follow-up period might be too short
to detect differences in complications. Treatment targets
are stricter than in the UKPDS, which may lead to more
hypoglycaemic events and a larger burden of treatment
and thus might inﬂuence psychological outcomes
negatively.
Methods
The current study is part of the ongoing international
ADDITION study in 3,057 screen-detected T2DM
patients, classiﬁed according to the 1999 WHO diag-
nostic criteria [8]. ADDITION consists of a screening
study and a subsequent intervention study with a mean
follow-up of 5 years, with a composite endpoint com-
prised of cardiovascular mortality and morbidity, revas-
cularisations, and amputations as the primary outcome
measure [7, 9]. The ADDITION-Netherlands study was
approved by the medical-ethical committee of the
University Medical Center Utrecht. In a stepwise popu-
lation-based screening programme (2002–2004) in 56,978
non-diabetic patients, aged 50–70 years, from 79 general
practices in the south-western region of the Netherlands,
we detected 586 new T2DM patients [10]. Of them, 498
were included in a single-blind trial with practice level
randomisation to intensiﬁed multi-factorial treatment (IT;
n = 255) or routine care (RC; n = 243). The other 88
patients declined participation (n = 69) or did not meet
the eligibility criteria (n = 19). Patients were blinded
to which treatment arm their general practitioner had
been randomised. Participants gave written informed
consent [11].
The IT protocol was target-driven. The treatment targets
are HbA1c\7.0%, but alterations to glucose-lowering
therapy when HbA1c[6.5%; blood pressure B135/
85 mmHg, but prescription of an ACE-inhibitor when
blood pressure[120/80 mmHg; prescription of acetylsal-
icylic acid 80 mg per day for patients treated with an
antihypertensive agent; total cholesterol B3.5 mmol/l
[7, 11]. Treatment goals in the RC group, originally
according to the 1999 guidelines of the Dutch College of
General Practitioners, were revised in 2006, but still less
strict than the IT protocol: HbA1c B7%, systolic blood
pressure B140 mmHg, total cholesterol B4.5 mmol/l, and
LDL-cholesterol B2.5 mmol/l; no acetylsalicylic acid had to
be prescribed [12].
Prior to entry into the study and after 3 years, par-
ticipants completed the Medical Outcomes Study 36-Item
Short Form Health Survey (SF-36) [13] and the Euro-
pean Quality of Life-5 Dimensions (EQ5D) [14] ques-
tionnaires. The SF-36 is a 36-item questionnaire that
measures perceived health, encompassing eight dimen-
sions: general health, vitality, mental health, physical
functioning, limitations due to physical difﬁculties (role
physical), bodily pain, social functioning, and limitations
due to emotional difﬁculties (role emotional) [13]. For
each dimension, item scores are transformed to a scale
ranging from 0 (worst health) to 100 (best health). The
Dutch version has been shown to be valid and reliable
[15]. The EQ5D is a measure of perceived health
including ﬁve dimensions: mobility, self care, usual
activities, pain/discomfort, and anxiety/depression [14].
Each dimension has three levels: no, some, and severe
limitations. So, there are 243 (i.e., 3
5) possible sets of
values for the EQ5D. All of these possible health states
have been valued by the general public, ranging from
-0.549 for severe problems with all dimensions to 1 for
full health. Values found in the UK have been validated
for the Netherlands.
After 4.5 years, participants completed the Diabetes
Treatment Satisfaction Questionnaire (DTSQ) [16] and the
Problem Areas In Diabetes scale (PAID) [17]. The DTSQ
contains a six-item scale assessing treatment satisfaction.
Each item is scored on a scale of 0–6; thus the total score of
the DTSQ ranges between 0 and 36, with higher scores
indicating greater satisfaction with treatment [16]. The
PAID is a self-report measure of diabetes-related distress,
consisting of 20 statements that were identiﬁed as common
negative emotions related to living with diabetes [17]. Each
item can be rated on a 5-point Likert scale ranging from 0
(‘‘not a problem’’) to 4 (‘‘a serious problem’’). The total
score is transformed to a 0–100 scale, with higher scores
indicating higher emotional distress. The Dutch version of
the PAID has good internal consistency and factorial
validity [18].
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baseline to the 3-year measurement in the SF-36 and EQ5D
scores. For effects on treatment satisfaction and diabetes-
related emotional distress, we analysed differences
(IT–RC) in the scores of the DTSQ and PAID scales after
4.5 years. We used random effects models to account for
clustering at the level of the general practitioner. We cal-
culated 95% conﬁdence intervals for the differences
between treatment arms and used a two-sided alpha of 0.05
to test signiﬁcance. A formal power calculation was not
carried out as these patient-reported outcome measures
were not the primary outcome measures for the interven-
tion study.
Results
Response rates for the different scores varied between 60
and 72% and did not differ for the IT and RC groups. The
IT and RC groups are well comparable with respect to
clinical, biochemical, and behavioural characteristics at
baseline [11]. This did not change when only people who
completed the questionnaires were taken into account,
except for systolic blood pressure (mean IT: 167.6 mmHg;
RC: 162.3 mmHg; P = 0.03) and mental health (P =
0.03; Table 1).
After 3 years (mean 2.97; SD 0.26), scores increased on
the SF-36 scales general health, vitality, and mental health
and decreased on the SF-36 scales role physical (statisti-
cally signiﬁcant in IT), bodily pain (statistically signiﬁ-
cantly in RC), and social functioning. None of the changes
in SF-36 or EQ5D differed signiﬁcantly between IT and
RC (Table 1).
Table 1 also displays the DTSQ and PAID scores at
4.5 years (mean 4.69; SD 0.62) in both treatment groups,
showing no differences between IT and RC.
Discussion
This study showed no effects of intensiﬁed treatment on
self-reported health status, satisfaction with diabetes
treatment, and diabetes-related emotional distress. We
examined a large group of screen-detected T2DM patients,
who were followed until 3–5 years after diagnosis. The
results address both diabetes-speciﬁc and generic outcomes
[19] and are highly relevant for patients.
To our knowledge, the ADDITION study is the ﬁrst
randomised trial on the effects of an intensiﬁed, multi-
factorial intervention in T2DM patients identiﬁed by
screening. Until now, only few randomised controlled trials
compared a multi-factorial treatment with a standard
treatment of T2DM, [6, 20]. The UKPDS showed no
effects of intensive treatment on perceived health [6].
Me ´nard et al. reported effects on quality of life in poorly
controlled patients with a longer duration of diabetes using
an adapted version of the Diabetes Quality of Life Measure
[21], indicating an improvement after 1 year in general
quality of life and life satisfaction, but not in diabetes-
related worry [20]. However, due to the shorter follow-up
period and different study population, these results are hard
to compare with ours.
A limitation might be the response rates. However, these
are in accordance with or even higher than in other studies
in the Netherlands [22]. Response rates were comparable
for IT and RC groups, and responders did not differ from
non-responders (results not shown). With the included
numbers of patients, we were able to detect differences up
to 7%, which was reported as a moderate effect [15], on all
of the reported scales except for SF-36 role physical and
role emotional (each 10%).
Another limitation might be that it was not possible
to include the DTSQ and PAID at baseline, as the
patients were screen-detected and did not know that
they had T2DM at that time. We cannot be sure
whether patients in both groups are similar with respect
to what they would have thought about treatment
satisfaction or diabetes-related distress. However, as
patients in the IT and RC groups were well comparable
with respect to clinical, biochemical, and behavioural
characteristics at baseline [11], we have no indications
that there would have been large differences in baseline
DTSQ and PAID values.
The scores on SF-36, EQ5D, PAID, and DTSQ indicate
an overall good psychological state of the participants,
probably because all patients are screen-detected. As a
consequence, patients have diabetes for only a few years,
with a few complications accordingly.
The ﬁnding that nor self-reported health status nor
treatment satisfaction or diabetes-related distress was
inﬂuenced by a multi-factorial intensiﬁcation of treatment
does imply that health care professionals do not have to
fear negative effects of an intensive treatment starting
immediately after diagnosing T2DM. Assuming that an
intensiﬁed treatment may decrease the risk of complica-
tions compared to routine care, one could expect a differ-
ence between both groups on the long run in favour of the
people who were treated intensively after their screen-
detected diagnosis. Patients should be followed up for a
longer period to assess the full impact on psychological
outcomes of screening for T2DM immediately followed by
intensiﬁed, multi-factorial treatment.
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